Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar versus metformin for insulin resistance and hormonal improvement in polycystic ovary syndrome
ChiCTR2500096097Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of chiglitazar in polycystic ovary syndrome (PCOS) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: testosterone, estradiol and 3 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
chiglitazar
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2500096097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096097.